Emerging drugs for the treatment of tobacco dependence: 2014 update

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: Tobacco dependence remains a global epidemic and the largest preventable cause of morbidity and mortality around the world. Smoking cessation has benefits at all ages but remains challenging for several reasons, among which are the complexities of nicotine addiction and limitations of available pharmacotherapies. Areas covered: This review summarizes current and emerging pharmacotherapies for the treatment of tobacco dependence, including first- and second-line recommended agents. Medications with alternative primary indications that have been investigated as potential treatments for tobacco dependence are also discussed. Articles reviewed were obtained through searches of PubMed, Ovid MEDLINE, ClinicalTrials.gov and the Pharmaprojects database. Expert opinion: Current evidence suggests that the two most effective pharmacotherapies to treat tobacco dependence are varenicline and combination nicotine replacement therapy. Alternative agents investigated demonstrate mixed rates of success in achieving long-term abstinence from smoking. No single pharmacotherapy will serve as a universally successful treatment given the complex underpinnings of tobacco dependence and individuality of smokers. The ultimate goal of tobacco research with respect to pharmacotherapeutic development continues to be providing clinicians with an armamentarium of drugs to choose from allowing for tailoring of treatment for smokers.

Original languageEnglish (US)
Pages (from-to)243-260
Number of pages18
JournalExpert Opinion on Emerging Drugs
Volume19
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Tobacco Use Disorder
Drug Therapy
Pharmaceutical Preparations
Nicotine
Therapeutics
Expert Testimony
Smoking Cessation
PubMed
Individuality
MEDLINE
Tobacco
Smoking
Databases
Morbidity
Mortality
Research

Keywords

  • Atomoxetine
  • Baclofen
  • Bupropion
  • Buspirone
  • Carvedilol
  • Clonidine
  • Cytisine
  • D-cycloserine
  • Emerging pharmacotherapies
  • EVT 302
  • GSK598809
  • Labetalol
  • Lobeline
  • Mecamylamine
  • N-acetylcysteine
  • Naltrexone
  • Nicotine replacement therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Emerging drugs for the treatment of tobacco dependence : 2014 update. / Elrashidi, Muhamad Y; Ebbert, Jon Owen.

In: Expert Opinion on Emerging Drugs, Vol. 19, No. 2, 2014, p. 243-260.

Research output: Contribution to journalArticle

@article{4d26b11cf1a44e9c91c2efa1f4115026,
title = "Emerging drugs for the treatment of tobacco dependence: 2014 update",
abstract = "Introduction: Tobacco dependence remains a global epidemic and the largest preventable cause of morbidity and mortality around the world. Smoking cessation has benefits at all ages but remains challenging for several reasons, among which are the complexities of nicotine addiction and limitations of available pharmacotherapies. Areas covered: This review summarizes current and emerging pharmacotherapies for the treatment of tobacco dependence, including first- and second-line recommended agents. Medications with alternative primary indications that have been investigated as potential treatments for tobacco dependence are also discussed. Articles reviewed were obtained through searches of PubMed, Ovid MEDLINE, ClinicalTrials.gov and the Pharmaprojects database. Expert opinion: Current evidence suggests that the two most effective pharmacotherapies to treat tobacco dependence are varenicline and combination nicotine replacement therapy. Alternative agents investigated demonstrate mixed rates of success in achieving long-term abstinence from smoking. No single pharmacotherapy will serve as a universally successful treatment given the complex underpinnings of tobacco dependence and individuality of smokers. The ultimate goal of tobacco research with respect to pharmacotherapeutic development continues to be providing clinicians with an armamentarium of drugs to choose from allowing for tailoring of treatment for smokers.",
keywords = "Atomoxetine, Baclofen, Bupropion, Buspirone, Carvedilol, Clonidine, Cytisine, D-cycloserine, Emerging pharmacotherapies, EVT 302, GSK598809, Labetalol, Lobeline, Mecamylamine, N-acetylcysteine, Naltrexone, Nicotine replacement therapy",
author = "Elrashidi, {Muhamad Y} and Ebbert, {Jon Owen}",
year = "2014",
doi = "10.1517/14728214.2014.899580",
language = "English (US)",
volume = "19",
pages = "243--260",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Emerging drugs for the treatment of tobacco dependence

T2 - 2014 update

AU - Elrashidi, Muhamad Y

AU - Ebbert, Jon Owen

PY - 2014

Y1 - 2014

N2 - Introduction: Tobacco dependence remains a global epidemic and the largest preventable cause of morbidity and mortality around the world. Smoking cessation has benefits at all ages but remains challenging for several reasons, among which are the complexities of nicotine addiction and limitations of available pharmacotherapies. Areas covered: This review summarizes current and emerging pharmacotherapies for the treatment of tobacco dependence, including first- and second-line recommended agents. Medications with alternative primary indications that have been investigated as potential treatments for tobacco dependence are also discussed. Articles reviewed were obtained through searches of PubMed, Ovid MEDLINE, ClinicalTrials.gov and the Pharmaprojects database. Expert opinion: Current evidence suggests that the two most effective pharmacotherapies to treat tobacco dependence are varenicline and combination nicotine replacement therapy. Alternative agents investigated demonstrate mixed rates of success in achieving long-term abstinence from smoking. No single pharmacotherapy will serve as a universally successful treatment given the complex underpinnings of tobacco dependence and individuality of smokers. The ultimate goal of tobacco research with respect to pharmacotherapeutic development continues to be providing clinicians with an armamentarium of drugs to choose from allowing for tailoring of treatment for smokers.

AB - Introduction: Tobacco dependence remains a global epidemic and the largest preventable cause of morbidity and mortality around the world. Smoking cessation has benefits at all ages but remains challenging for several reasons, among which are the complexities of nicotine addiction and limitations of available pharmacotherapies. Areas covered: This review summarizes current and emerging pharmacotherapies for the treatment of tobacco dependence, including first- and second-line recommended agents. Medications with alternative primary indications that have been investigated as potential treatments for tobacco dependence are also discussed. Articles reviewed were obtained through searches of PubMed, Ovid MEDLINE, ClinicalTrials.gov and the Pharmaprojects database. Expert opinion: Current evidence suggests that the two most effective pharmacotherapies to treat tobacco dependence are varenicline and combination nicotine replacement therapy. Alternative agents investigated demonstrate mixed rates of success in achieving long-term abstinence from smoking. No single pharmacotherapy will serve as a universally successful treatment given the complex underpinnings of tobacco dependence and individuality of smokers. The ultimate goal of tobacco research with respect to pharmacotherapeutic development continues to be providing clinicians with an armamentarium of drugs to choose from allowing for tailoring of treatment for smokers.

KW - Atomoxetine

KW - Baclofen

KW - Bupropion

KW - Buspirone

KW - Carvedilol

KW - Clonidine

KW - Cytisine

KW - D-cycloserine

KW - Emerging pharmacotherapies

KW - EVT 302

KW - GSK598809

KW - Labetalol

KW - Lobeline

KW - Mecamylamine

KW - N-acetylcysteine

KW - Naltrexone

KW - Nicotine replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=84901287627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901287627&partnerID=8YFLogxK

U2 - 10.1517/14728214.2014.899580

DO - 10.1517/14728214.2014.899580

M3 - Article

C2 - 24654737

AN - SCOPUS:84901287627

VL - 19

SP - 243

EP - 260

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -